Loading
institutionsInstitution
The Mount Sinai Hospital / Tisch Cancer Institute
Mount Sinai is a New York academic centre with strengths in myeloma and cancer immunology.
Also called: Mount Sinai Tisch Cancer CenterTisch Cancer Institute
Overview
The Mount Sinai Hospital and its Tisch Cancer Institute form a New York academic centre with NCI clinical designation, ranked thirty-fourth in the Newsweek/Statista oncology list, and its strengths are multiple myeloma and cancer immunology. Its myeloma programme is associated with Sundar Jagannath, its immunology with Miriam Merad and Nina Bhardwaj, and it has a record in neoadjuvant immunotherapy, with Joshua Brody, Thomas U. Marron, Matthew D. Galsky, Josep M. Llovet and Ramon E. Parsons among the people OnCo lists. OnCo links it to the tumour dormancy pathway, to the NIAGARA bladder cancer paper, and to ideas on keeping disseminated cells asleep and on turning one tumour into a vaccine for the others. What decides which disseminated cells ever colonise is the open question its dormancy work asks. Its myeloma and tumour immunology programmes are the ones to read.
Location
New York, US
Type
hospital
Newsweek 2026 oncology rank
#34
NCI designation
clinical
OnCo score
#47 · 54 points (26 Newsweek + 8 NCI + 20 from 10 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Icahn School of Medicine at Mount Sinai, including child institutions. 1,722 works · 19,564 citations · 66% open access · 10% clinical trials · 3% reviews.
Oncology works per year
3242022
3722023
4192024
3522025
2552026
Most works
- Thomas U. Marron41 works
- Joshua Brody40 works
- Sundar Jagannath37 works
- Shambavi Richard37 works
- Sacha Gnjatic34 works
- Samir Sunil Parekh33 works
- Nicholas Gulati33 works
- Adriana Rossi30 works
- Fred R. Hirsch28 works
- Miriam Merad27 works
Most cited
- Myeloma
- Tumour immunology
Josep M. Llovet
Director, Liver Cancer Program, Icahn School of Medicine at Mount Sinai; Professor, University of Barcelona
Hepatocellular carcinomaTargeted therapyStaging systems
Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system.
Joseph A. Sparano
Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Early breast cancerGenomic assaysChemotherapy de-escalation
Led TAILORx, which showed most women with intermediate Oncotype scores can safely skip chemotherapy.
Joshua Brody
Director, Lymphoma Immunotherapy Program
LymphomaIn situ vaccinationBispecific antibodies
Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.
Matthew D. Galsky
Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer
Bladder cancerImmunotherapyBladder preservation
Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.
Miriam Merad
Director, Marc and Jennifer Lipschultz Precision Immunology Institute; Chair, Department of Immunology and Immunotherapy
Myeloid cellsTumour-associated macrophagesSingle-cell immunology
Mapped how macrophages and dendritic cells in tumours suppress immunity, opening new immunotherapy targets.
Nina Bhardwaj
Director of Immunotherapy; Ward-Coleman Chair in Cancer Research
Dendritic cellsCancer vaccinesPersonalised neoantigen vaccines
Nina Bhardwaj is a dendritic-cell immunologist running personalised neoantigen vaccine trials.
Ramon E. Parsons
Director, Tisch Cancer Institute; Chair, Department of Oncological Sciences
PTEN and PI3K signallingBreast cancer geneticsTumour suppressors
Discovered the tumour-suppressor gene PTEN, one of the most frequently lost genes in cancer.
Sundar Jagannath
Director, Center of Excellence for Multiple Myeloma
Multiple myelomaNovel agentsBispecific antibodies
Veteran myeloma trialist who helped bring proteasome inhibitors and bispecifics to patients.
Thomas J. Fuchs
Dean of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai; Co-founder, Paige
Computational pathologyClinical-grade AIMachine learning at scale
Trained the first clinical-grade AI on tens of thousands of slides, leading to the first FDA-authorised AI pathology product.
Thomas U. Marron
Director, Early Phase Trials Unit
Neoadjuvant immunotherapyLiver cancerPhase 1 trials
Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.
Similar pages
- TermLate recurrence
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, What decides which disseminated cells ever colonise?, Tumour dormancy.
- InstitutionMontefiore Einstein Comprehensive Cancer Center
Shares New York Proton Center, National Cancer Institute (NIH).
- TermDisseminated tumour cells (DTCs)
Shares What decides which disseminated cells ever colonise?, Tumour dormancy.
- PathwayThe metastatic cascade
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, What decides which disseminated cells ever colonise?, Tumour dormancy.
- PersonPadmanee Sharma
Shares Parker Institute for Cancer Immunotherapy, Bladder & urothelial cancer.
- InstitutionCold Spring Harbor Laboratory
Shares What decides which disseminated cells ever colonise?, Tumour dormancy, National Cancer Institute (NIH).
- InstitutionHospital Clínic de Barcelona / IDIBAPS
Shares Josep M. Llovet, Multiple myeloma.
- PathwayOestrogen receptor signalling
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, Tumour dormancy.